Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

Toshiki Natazuka; Toru Yamaguchi; Tohru Murayama; Masaaki Fukase; Toshimitsu Matsui; Takashi Isobe; Kazuo Chihara

doi:10.1016/0925-5710(94)00330-H

Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

Toshiki Natazuka, Toru Yamaguchi, Tohru Murayama, Masaaki Fukase, Toshimitsu Matsui, Takashi Isobe, Kazuo Chihara

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-κ type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of α-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.

Original language	English
Pages (from-to)	263-265
Number of pages	3
Journal	International Journal of Hematology
Volume	60
Issue number	4
DOIs	https://doi.org/10.1016/0925-5710(94)00330-H
State	Published - Dec 1994
Externally published	Yes

Access to Document

10.1016/0925-5710(94)00330-H

Cite this

@article{d866dba7cd224124b5dcde3e167fbc08,

title = "Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma",

abstract = "A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-κ type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of α-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.",

author = "Toshiki Natazuka and Toru Yamaguchi and Tohru Murayama and Masaaki Fukase and Toshimitsu Matsui and Takashi Isobe and Kazuo Chihara",

year = "1994",

month = dec,

doi = "10.1016/0925-5710(94)00330-H",

language = "English",

volume = "60",

pages = "263--265",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer",

number = "4",

}

TY - JOUR

T1 - Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

AU - Natazuka, Toshiki

AU - Yamaguchi, Toru

AU - Murayama, Tohru

AU - Fukase, Masaaki

AU - Matsui, Toshimitsu

AU - Isobe, Takashi

AU - Chihara, Kazuo

PY - 1994/12

Y1 - 1994/12

N2 - A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-κ type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of α-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.

AB - A 35-year-old male presented with chronic myelomonocytic leukemia (CMMoL) after 6.5 years of alkylating agent therapy for IgG-κ type multiple myeloma. The total dose of melphalan was 0.648 g. CMMoL was stable with weekly injection of α-interferon for one year. Thereafter, monocytosis and thrombocytopenia aggravated, and the patient died of disseminating intravascular coagulation. Prolonged drug therapy can induce CMMoL, as well as other myelodysplastic syndromes.

UR - https://www.scopus.com/pages/publications/0028581993

U2 - 10.1016/0925-5710(94)00330-H

DO - 10.1016/0925-5710(94)00330-H

M3 - Article

C2 - 7894029

AN - SCOPUS:0028581993

SN - 0925-5710

VL - 60

SP - 263

EP - 265

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 4

ER -

Chronic myelomonocytic leukemia following prolonged alkylating agent therapy for multiple myeloma

Abstract

Access to Document

Fingerprint

Cite this